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Motivation
B  cell  Lymphoma 6  (BCL6)  and  Leukaemia/Lymphoma related  factor  (LRF)  are  Pok-
proteins over-expressed in some types of Non–Hodgkin’s lymphoma. BCL6 is located on 
chromosome  3  in  the  breakpoint  affecting  3q27  band  which  is  the  most  frequent  
translocation in Non-Hodgkin’s lymphomas. This gene is a transcriptional repressor whose 
principal effect is to thwart the response to DNA damage by directly inhibiting both p53 and 
the cell cycle inhibitor p21. In lymphoma cells BCL6 prevents apoptosis induced by DNA 
damage. LRF, encoded by the Zbtb7a gene, also known as Pokemon, is a transcriptional  
repressor  involved  in  many  cellular  processes  as  viral  infection,  differentiation, 
inflammation and oncogenesis. LRF plays an important role as proto-oncogene in Non- 
Hodgkin's lymphomas: LRF indirectly inhibits p53, by repressing p14/ARF with consequent 
activation of MDM2 followed by p53 degradation. LRF is often aberrantly over-expressed 
in  association  with  BCL6  in  diffuse  large  B  cell  lymphoma  (DLBCL)  and  follicular 
lymphoma  (FL),  the  commonest  types  of  Non-  Hodgkin's  lymphomas. It  has  been 
demonstrated  that  microRNAs,  a  class  of  endogenous  22-25  nt  single  stranded  RNA 
molecules, regulate target gene expression at the post-transcriptional level by binding with 
imperfect complementarity to specific regions of the 3’UTR of the target mRNA and act by 
repressing its translation. Recently miRNAs were shown to participate in the network of 
oncogenes  and  tumour  suppressors,  behaving  either  as  tumour  suppressors  or  as 
oncogenes,  with  the  consequent  implication  of  their  potential  use  as  novel  anti 
tumourigenic drug. For these reason we investigated the role of miRNAs in the complex 
network connecting BCL6 and LRF in follicular lymphoma.
Results 
In this work we focused our attention on the possible correlation between BCL6 and LRF 
in  DOHH2  cells  taking  into  consideration  miRNAs  which  potentially  link  these  two 
oncogenes.  Using  our  data  and  data  present  in  the  literature,  we  reconstructed  a 
hypothetical circuit connecting BCL6 and LRF. A negative feedback loop appears to link 
BCL6 to  LRF, however  in DLBCL and FL both genes are over  expressed; these data 
strongly indicate that the negative feedback loop is bypassed in tumour cells to favour high 
proliferation rate. 
Different approaches were used to modulate the expression of BCL6 and LRF in Dohh2, a 
cell line derived from Follicular Lymphoma. A) Dohh2 cells were treated with etoposide, a 
chemotherapeutic agent that is able to reduce both BCL6 and LRF. Our results show that  
the reduction of BCL-6/LRF cells is followed by cell proliferation block and over-expression 
of  miR-145,  a  tumour  suppressor  miRNA,  under  p53  control,  which  targets  c-myc. 
Interestingly  while  c-myc  was  down  regulated  as  expected,  E2F1  resulted  to  be  up 
regulated. B) To verify whether miR-145 could substitute for etoposide treatment miR-145 
was transiently over expressed in Dohh2 cells.  Although the network was influenced by 
miR-145 and both BCL6 and LRF were down regulated, no change in the proliferation rate 
of Dohh2 cells was found. Unexpectedly p53 was also markedly down regulated which 
could in part  explain why cell  proliferation was not inhibited notwithstanding BCL6/LRF 
decrease. C) In order to see the effect of a prolonged increase of miR-145, stably BCL6 
silenced Dohh2 cells were used. In this case miR-145 was stably up regulated due to p53 
increase  and  LRF  was  down  regulated,  yet  again  no  effect  on  cell  proliferation  was 
observed. Our results clearly show that in the tumour Dohh2 cells BCL6 and LRF are 
always  co-regulated  (contrary  to  the  hypothetical  network);  however  their  concomitant 
down regulation is not sufficient to determine cell proliferation block as cells appear to find 
a new equilibrium to counteract these anti-proliferative signals. We suggest that the down 
regulation of BCL6/LRF must be concomitant to the upregulation of the tumour suppressor 
p53 and the proto-oncogene E2F1 to influence the cell cycle and that miRNAs (such as 
miR-145 and miR-20) are part of these regulatory mechanisms. 
